citalopram has been researched along with Aging in 46 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the correlates of sleep disturbance and to assess escitalopram treatment effects of depression on sleep disturbance in patients with acute coronary syndrome (ACS)." | 9.20 | Correlates and Escitalopram Treatment Effects on Sleep Disturbance in Patients with Acute Coronary Syndrome: K-DEPACS and EsDEPACS. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Stewart, R; Yoon, JS, 2015) |
| "Escitalopram was well tolerated, and the only detected side effects, nausea and headache, were mild and transient." | 5.40 | The beneficial effect of escitalopram on obsessive-compulsive-related musical hallucinations in elderly patients with hearing impairment: a case series. ( Bergman, J; Pashinian, A; Poyurovsky, M; Weizman, A, 2014) |
| "To investigate the correlates of sleep disturbance and to assess escitalopram treatment effects of depression on sleep disturbance in patients with acute coronary syndrome (ACS)." | 5.20 | Correlates and Escitalopram Treatment Effects on Sleep Disturbance in Patients with Acute Coronary Syndrome: K-DEPACS and EsDEPACS. ( Ahn, Y; Bae, KY; Hong, YJ; Jeong, MH; Kang, HJ; Kim, JM; Kim, SW; Shin, IS; Stewart, R; Yoon, JS, 2015) |
| "The effect of aging on steady-state plasma concentrations of citalopram (CIT) and desmethylcitalopram (DCIT) was investigated in 128 depressive patients treated with 10-80 mg/day CIT." | 5.11 | Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. ( Baumann, P; Brawand-Amey, M; Brogli, C; Cochard, N; de Mendonça Lima, CA; Eap, CB; Jacquet, S; Powell-Golay, K, 2005) |
| " Twenty LLD patients meeting DSM-IV criteria for a current major depressive episode and 20 non-depressed controls underwent clinical and neuropsychological assessments, magnetic resonance imaging to measure gray matter volumes and high-resolution positron emission tomography (PET) scanning to measure 5-HTT before and after 10-12 weeks of treatment with Citalopram or Sertraline (patients only)." | 4.02 | Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression. ( Bigos, KL; Brasic, J; Dannals, RF; Gould, NF; Hall, AW; Holt, DP; Joo, JH; Kraut, M; Kuwabara, H; Mathews, WB; Nandi, A; Nassery, N; Savonenko, A; Smith, GS; Workman, CI, 2021) |
| "Nine LLD patients and seven non-depressed control subjects underwent clinical and cognitive evaluations as well as brain magnetic resonance imaging and PET studies of cerebral glucose metabolism at baseline, after 8 weeks of treatment with citalopram for a major depressive episode (patients only), and at an approximately 2-year follow-up." | 3.79 | Longitudinal studies of cerebral glucose metabolism in late-life depression and normal aging. ( Chaly, T; Dhawan, V; Eidelberg, D; Hermann, CR; Kramer, E; Ma, Y; Marano, CM; Smith, GS; Workman, CI, 2013) |
| "Information processing bias was evaluated in a sample of 25 older adults with generalized anxiety disorder (GAD) over the course of 12 weeks of escitalopram pharmacotherapy." | 3.79 | Information processing bias and pharmacotherapy outcome in older adults with generalized anxiety disorder. ( Nguyen, H; Petkus, AJ; Steiner, AR; Wetherell, JL, 2013) |
| "The purpose of this study was to analyze the antidepressant-like actions of estradiol valerate (1 or 2 mg/rat, single injection) or citalopram (5 or 10 mg/kg, chronically administered for 21 days) given independently or combined at low doses, to middle-aged ovariectomized female rats, as a model of human menopause." | 3.76 | Estradiol valerate elicits antidepressant-like effects in middle-aged female rats under chronic mild stress. ( Fernández-Guasti, A; Romano-Torres, M, 2010) |
| " The neuroendocrine and cerebral metabolic response to the acute administration of the selective serotonin reuptake inhibitor, citalopram (40mg, IV), was measured in 17 normal control subjects using positron emission tomography (PET) to evaluate changes in serotonin function with normal aging." | 3.72 | Serotonin modulation of cerebral glucose metabolism in normal aging. ( Barnes, A; Eidelberg, D; Goldberg, S; Kirshner, M; Kramer, E; Ma, Y; Pollock, BG; Robeson, K; Smith, GS, 2004) |
| "Participants with GAD and coprescribed benzodiazepines were treated with a lower mean dosage of escitalopram and were less likely to complete the trial; there was no difference in adherence or treatment response." | 2.94 | Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes. ( Altmann, H; Blumberger, DM; Gebara, MA; Karp, JF; Lenze, EJ; Mulsant, BH; Reynolds, CF; Stahl, ST, 2020) |
| "We investigated whether treating depression in older participants impacted on arterial stiffness, a known cardiovascular disease risk factor and a clinical marker of arterial aging." | 2.78 | Depression treatment selectively modifies arterial stiffness in older participants. ( Assisi, AP; Fedullo, F; Gianni, W; Modestino, A; Scuteri, A, 2013) |
| "While treatment of depression in major depressive disorder may partially ameliorate cognitive deficits, the cognitive effects of antidepressant medications in patients with schizophrenia or schizoaffective disorder and SSD are unknown." | 2.77 | Does antidepressant treatment improve cognition in older people with schizophrenia or schizoaffective disorder and comorbid subsyndromal depression? ( Dawes, SE; Golshan, S; Kasckow, J; Meeks, T; Mohamed, S; Palmer, BW; Zisook, S, 2012) |
| "Citalopram-treated patients with DRI did significantly worse than placebo-treated patients with DRI." | 2.75 | Antidepressant medication and executive dysfunction: a deleterious interaction in late-life depression. ( Culang, ME; Devanand, DP; Keilp, JG; Roose, SP; Rutherford, BR; Sneed, JR, 2010) |
| "The citalopram group was significantly older than the sertraline group and had more severe SH (72% vs." | 2.70 | MRI subcortical hyperintensities in old and very old depressed outpatients: the important role of age in late-life depression. ( Boyle, P; Correia, S; Krishnan, KR; Lavretsky, H; Malloy, P; Roose, S; Sackheim, H; Salloway, S; Schneider, L, 2002) |
| "To compare the steady-state pharmacokinetics of citalopram after multiple-dose administration in elderly and young subjects, and to correlate pharmacokinetic measurements with tolerability." | 2.69 | Steady-state pharmacokinetics of citalopram in young and elderly subjects. ( Abramowitz, W; Gutierrez, M, 2000) |
| " A nonlinear mixed effects population pharmacokinetic modeling approach was used to describe the pharmacokinetics of R- and S-citalopram and their primary metabolite (desmethylcitalopram)." | 1.43 | A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. ( Akil, A; Avramopoulos, D; Bies, RR; Devanand, DP; Lyketsos, CG; Mintzer, JE; Pollock, BG; Porsteinsson, AP; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2016) |
| " These data reveal age- and genotype-dependent shifts in the dose-response for escitalopram to produce antidepressant-like effects, which vary with SERT expression, and may contribute to the limited therapeutic response to SSRIs in juveniles and adolescents." | 1.43 | Ontogeny of SERT Expression and Antidepressant-like Response to Escitalopram in Wild-Type and SERT Mutant Mice. ( Daws, LC; Gould, GG; Koek, W; Mitchell, NC, 2016) |
| "Escitalopram was well tolerated, and the only detected side effects, nausea and headache, were mild and transient." | 1.40 | The beneficial effect of escitalopram on obsessive-compulsive-related musical hallucinations in elderly patients with hearing impairment: a case series. ( Bergman, J; Pashinian, A; Poyurovsky, M; Weizman, A, 2014) |
| "Escitalopram (n=3298) was administered at doses between 5 and 20mg/day." | 1.39 | The cardiovascular safety profile of escitalopram. ( Kennedy, SH; Larsen, KG; Reines, E; Thase, ME, 2013) |
| "Citalopram treatment had no effect on serum insulin levels in 15-week-old mice." | 1.31 | Effect of serotonin reuptake inhibitor on syndrome development in obese hyperglycemic mice (Umeå ob/ob). ( Lindström, P; Rooth, P; Thrybom, T, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (8.70) | 18.7374 |
| 1990's | 8 (17.39) | 18.2507 |
| 2000's | 10 (21.74) | 29.6817 |
| 2010's | 20 (43.48) | 24.3611 |
| 2020's | 4 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, YJ | 1 |
| Gong, WG | 1 |
| Ren, QG | 1 |
| Zhang, ZJ | 1 |
| Altmann, H | 1 |
| Stahl, ST | 1 |
| Gebara, MA | 1 |
| Lenze, EJ | 1 |
| Mulsant, BH | 1 |
| Blumberger, DM | 1 |
| Reynolds, CF | 1 |
| Karp, JF | 1 |
| Henn, L | 1 |
| Zanta, NC | 1 |
| Girardi, CEN | 1 |
| Suchecki, D | 1 |
| Smith, GS | 3 |
| Kuwabara, H | 1 |
| Gould, NF | 1 |
| Nassery, N | 1 |
| Savonenko, A | 1 |
| Joo, JH | 1 |
| Bigos, KL | 1 |
| Kraut, M | 1 |
| Brasic, J | 1 |
| Holt, DP | 1 |
| Hall, AW | 1 |
| Mathews, WB | 1 |
| Dannals, RF | 1 |
| Nandi, A | 1 |
| Workman, CI | 2 |
| Klaassens, BL | 1 |
| van Gerven, JMA | 1 |
| Klaassen, ES | 1 |
| van der Grond, J | 1 |
| Rombouts, SARB | 1 |
| Thase, ME | 1 |
| Larsen, KG | 1 |
| Reines, E | 1 |
| Kennedy, SH | 1 |
| Kemp, AH | 1 |
| Outhred, T | 1 |
| Saunders, S | 1 |
| Brunoni, AR | 1 |
| Nathan, PJ | 1 |
| Malhi, GS | 1 |
| Bergman, J | 1 |
| Pashinian, A | 1 |
| Weizman, A | 1 |
| Poyurovsky, M | 1 |
| Waade, RB | 1 |
| Hermann, M | 1 |
| Moe, HL | 1 |
| Molden, E | 1 |
| Andreescu, C | 1 |
| Sheu, LK | 1 |
| Tudorascu, D | 1 |
| Gross, JJ | 1 |
| Walker, S | 1 |
| Banihashemi, L | 1 |
| Aizenstein, H | 1 |
| Kim, JM | 1 |
| Stewart, R | 1 |
| Bae, KY | 1 |
| Kang, HJ | 1 |
| Kim, SW | 1 |
| Shin, IS | 1 |
| Hong, YJ | 1 |
| Ahn, Y | 1 |
| Jeong, MH | 1 |
| Yoon, JS | 1 |
| Akil, A | 1 |
| Bies, RR | 1 |
| Pollock, BG | 2 |
| Avramopoulos, D | 1 |
| Devanand, DP | 2 |
| Mintzer, JE | 1 |
| Porsteinsson, AP | 1 |
| Schneider, LS | 1 |
| Weintraub, D | 1 |
| Yesavage, J | 1 |
| Shade, DM | 1 |
| Lyketsos, CG | 1 |
| Mitchell, NC | 1 |
| Gould, GG | 1 |
| Koek, W | 1 |
| Daws, LC | 1 |
| Marner, L | 1 |
| Gillings, N | 1 |
| Madsen, K | 1 |
| Erritzoe, D | 1 |
| Baaré, WF | 1 |
| Svarer, C | 1 |
| Hasselbalch, SG | 1 |
| Knudsen, GM | 2 |
| Sneed, JR | 1 |
| Culang, ME | 1 |
| Keilp, JG | 1 |
| Rutherford, BR | 1 |
| Roose, SP | 1 |
| Herrera-Pérez, JJ | 1 |
| Martínez-Mota, L | 1 |
| Fernández-Guasti, A | 2 |
| Romano-Torres, M | 1 |
| Masalova, OO | 1 |
| Sapronov, NS | 1 |
| Holm, P | 1 |
| Ettrup, A | 1 |
| Klein, AB | 1 |
| Santini, MA | 1 |
| El-Sayed, M | 1 |
| Elvang, AB | 1 |
| Stensbøl, TB | 1 |
| Mikkelsen, JD | 1 |
| Aznar, S | 1 |
| Berardelli, R | 1 |
| Margarito, E | 1 |
| Ghiggia, F | 1 |
| Picu, A | 1 |
| Balbo, M | 1 |
| Bonelli, L | 1 |
| Giordano, R | 1 |
| Karamouzis, I | 1 |
| Bo, M | 1 |
| Ghigo, E | 1 |
| Arvat, E | 1 |
| Tecco, J | 1 |
| Monreal, J | 1 |
| Staner, L | 1 |
| Dawes, SE | 1 |
| Palmer, BW | 1 |
| Meeks, T | 1 |
| Golshan, S | 1 |
| Kasckow, J | 1 |
| Mohamed, S | 1 |
| Zisook, S | 1 |
| Marano, CM | 1 |
| Kramer, E | 2 |
| Hermann, CR | 1 |
| Ma, Y | 2 |
| Dhawan, V | 1 |
| Chaly, T | 1 |
| Eidelberg, D | 2 |
| Scuteri, A | 1 |
| Modestino, A | 1 |
| Fedullo, F | 1 |
| Assisi, AP | 1 |
| Gianni, W | 1 |
| Steiner, AR | 1 |
| Petkus, AJ | 1 |
| Nguyen, H | 1 |
| Wetherell, JL | 1 |
| Salloway, S | 1 |
| Correia, S | 1 |
| Boyle, P | 1 |
| Malloy, P | 1 |
| Schneider, L | 1 |
| Lavretsky, H | 1 |
| Sackheim, H | 1 |
| Roose, S | 1 |
| Krishnan, KR | 1 |
| Goldberg, S | 1 |
| Barnes, A | 1 |
| Robeson, K | 1 |
| Kirshner, M | 1 |
| de Mendonça Lima, CA | 1 |
| Baumann, P | 1 |
| Brawand-Amey, M | 1 |
| Brogli, C | 1 |
| Jacquet, S | 1 |
| Cochard, N | 1 |
| Powell-Golay, K | 1 |
| Eap, CB | 1 |
| Uys, JD | 1 |
| Muller, CJ | 1 |
| Marais, L | 1 |
| Harvey, BH | 1 |
| Stein, DJ | 1 |
| Daniels, WM | 1 |
| Alexopoulos, GS | 1 |
| Murphy, CF | 1 |
| Gunning-Dixon, FM | 1 |
| Kalayam, B | 1 |
| Katz, R | 1 |
| Kanellopoulos, D | 1 |
| Etwaroo, GR | 1 |
| Klimstra, S | 1 |
| Foxe, JJ | 1 |
| Reis, M | 1 |
| Chermá, MD | 1 |
| Carlsson, B | 1 |
| Bengtsson, F | 1 |
| Kozisek, ME | 1 |
| Middlemas, D | 1 |
| Bylund, DB | 1 |
| Baker, PC | 4 |
| Goodrich, CA | 1 |
| Fredricson Overø, K | 1 |
| Leroux-Nicollet, I | 1 |
| Costentin, J | 1 |
| Leinonen, E | 1 |
| Lepola, U | 1 |
| Koponen, H | 1 |
| Kinnunen, I | 1 |
| Bennett-Clarke, CA | 1 |
| Chiaia, NL | 1 |
| Rhoades, RW | 1 |
| Hebert, MA | 2 |
| Gerhardt, GA | 2 |
| Gutierrez, M | 1 |
| Abramowitz, W | 1 |
| Thrybom, T | 1 |
| Rooth, P | 1 |
| Lindström, P | 1 |
| Urbá-Holmgren, R | 1 |
| Holmgren, B | 1 |
| Leon, BA | 1 |
| Ugarte, A | 1 |
| Hoff, KM | 3 |
| D'Amato, RJ | 1 |
| Blue, ME | 1 |
| Largent, BL | 1 |
| Lynch, DR | 1 |
| Ledbetter, DJ | 1 |
| Molliver, ME | 1 |
| Snyder, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Incomplete Response in Late Life Depression: Getting to Remission[NCT00892047] | Phase 4 | 468 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Pharmacotherapy of Late-Life Generalized Anxiety Disorder[NCT00105586] | Phase 4 | 177 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Efficacy and Safety of Escitalopram in the Treatment of Depressive Patients With Acute Coronary Artery Syndrome: A Double-blind Placebo-controlled Trial[NCT00419471] | Phase 4 | 300 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| The Role of Sex Steroids and Serotonin Brain Dynamics in Perinatal Mental Health[NCT03795688] | 100 participants (Actual) | Observational [Patient Registry] | 2019-01-24 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of participants who developed clinically significant akathisia. (NCT00892047)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 1: Venlafaxine Plus Aripiprazole | 26.7 |
| 2: Placebo Comparator | 12.2 |
percentage of participants who reported suicidal ideation during treatment but not at baseline (NCT00892047)
Timeframe: 12 weeks
| Intervention | percent of participants (Number) |
|---|---|
| 1: Venlafaxine Plus Aripiprazole | 21.3 |
| 2: Placebo Comparator | 29.2 |
Percentage of participants who develop signs of parkinsonism (NCT00892047)
Timeframe: 12weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 1: Venlafaxine Plus Aripiprazole | 17.4 |
| 2: Placebo Comparator | 2.5 |
The Montgomery-Asberg Depression Rating Scale (MADRS) is a clinician rated ten item instrument assessing depression symptoms. Possible scores range from 0-60; higher scores indicate greater severity of depression. Remission defined as score of 10 or less based on the MADRS. (NCT00892047)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 1: Venlafaxine Plus Aripiprazole | 44 |
| 2: Placebo Comparator | 29 |
percentage of participants (NCT00892047)
Timeframe: 12 weeks
| Intervention | percent of participants (Number) |
|---|---|
| 1: Venlafaxine Plus Aripiprazole | 1.3 |
| 2: Placebo Comparator | 0 |
Weight change in kilograms (NCT00892047)
Timeframe: Baseline through12 weeks
| Intervention | kilograms (Mean) |
|---|---|
| 1: Venlafaxine Plus Aripiprazole | 1.93 |
| 2: Placebo Comparator | 0.01 |
Cumulative incident response of anxiety symptom improvement on CGI-I, with 1 (very much improved) to 2 (much improved) indicated as response. Scores synthesized from anxiety rating scale scores, including Penn State Worry Questionnaire (PSWQ) and Hamilton Anxiety Scale (HamA). (NCT00105586)
Timeframe: Measured at Weeks 1-12
| Intervention | participants (Number) |
|---|---|
| Placebo | 51 |
| Escitalopram | 69 |
Role -emotional impairment score from the Late-Life Function and Disability Instrument (min score=0, significant impairment; max score=100, no impairment). (NCT00105586)
Timeframe: Measured at Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Week 0 SF-36 Role-Emotional Impairment | Week 12 SF-36 Role-Emotional Impairment | |
| Escitalopram (1) | 42.19 | 62.50 |
| Placebo (2) | 53.42 | 56.16 |
13 trials available for citalopram and Aging
| Article | Year |
|---|---|
Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes.
Topics: Aged; Aged, 80 and over; Aging; Antidepressive Agents, Second-Generation; Anxiety Disorders; Benzodi | 2020 |
Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes.
Topics: Aged; Aged, 80 and over; Aging; Antidepressive Agents, Second-Generation; Anxiety Disorders; Benzodi | 2020 |
Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes.
Topics: Aged; Aged, 80 and over; Aging; Antidepressive Agents, Second-Generation; Anxiety Disorders; Benzodi | 2020 |
Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes.
Topics: Aged; Aged, 80 and over; Aging; Antidepressive Agents, Second-Generation; Anxiety Disorders; Benzodi | 2020 |
Serotonergic and cholinergic modulation of functional brain connectivity: A comparison between young and older adults.
Topics: Adolescent; Adult; Aged; Aging; Cerebral Cortex; Cholinesterase Inhibitors; Citalopram; Connectome; | 2018 |
Impact of escitalopram on vagally mediated cardiovascular function in healthy participants: implications for understanding differential age-related, treatment emergent effects.
Topics: Adult; Aging; Antidepressive Agents, Second-Generation; Citalopram; Cross-Over Studies; Double-Blind | 2014 |
Emotion reactivity and regulation in late-life generalized anxiety disorder: functional connectivity at baseline and post-treatment.
Topics: Aged; Aging; Anxiety Disorders; Brain Mapping; Case-Control Studies; Cerebral Cortex; Citalopram; Em | 2015 |
Correlates and Escitalopram Treatment Effects on Sleep Disturbance in Patients with Acute Coronary Syndrome: K-DEPACS and EsDEPACS.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Citalopram; | 2015 |
Antidepressant medication and executive dysfunction: a deleterious interaction in late-life depression.
Topics: Aged; Aged, 80 and over; Aging; Citalopram; Depressive Disorder; Executive Function; Female; Geriatr | 2010 |
Neuroendocrine effects of citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Aging; Citalopram; Dehydroepiandrosterone; Humans; Hydroco | 2010 |
Does antidepressant treatment improve cognition in older people with schizophrenia or schizoaffective disorder and comorbid subsyndromal depression?
Topics: Adult; Aging; Antidepressive Agents; Citalopram; Cognition Disorders; Comorbidity; Depression; Doubl | 2012 |
Depression treatment selectively modifies arterial stiffness in older participants.
Topics: Aged; Aging; Antidepressive Agents; Antidepressive Agents, Second-Generation; Blood Pressure; Cardio | 2013 |
MRI subcortical hyperintensities in old and very old depressed outpatients: the important role of age in late-life depression.
Topics: Age of Onset; Aged; Aging; Antidepressive Agents, Second-Generation; Brain; Citalopram; Dementia, Va | 2002 |
Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients.
Topics: Aged; Aged, 80 and over; Aging; Antidepressive Agents; Citalopram; Depression; Dose-Response Relatio | 2005 |
Therapeutic drug monitoring of escitalopram in an outpatient setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Body Size; Citalopram; Depression; Dose-Response | 2007 |
Steady-state pharmacokinetics of citalopram in young and elderly subjects.
Topics: Administration, Oral; Adult; Aged; Aging; Antidepressive Agents, Second-Generation; Citalopram; Dose | 2000 |
33 other studies available for citalopram and Aging
| Article | Year |
|---|---|
Escitalopram Alleviates Alzheimer's Disease-Type Tau Pathologies in the Aged P301L Tau Transgenic Mice.
Topics: Aging; Alzheimer Disease; Animals; Citalopram; Humans; Injections, Intraperitoneal; Male; Mice; Mice | 2020 |
Chronic Escitalopram Treatment Does Not Alter the Effects of Neonatal Stress on Hippocampal BDNF Levels, 5-HT
Topics: Aging; Animals; Animals, Newborn; Behavior, Animal; Body Weight; Brain-Derived Neurotrophic Factor; | 2021 |
Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression.
Topics: Affect; Aged; Aged, 80 and over; Aging; Antidepressive Agents; Brain; Citalopram; Depressive Disorde | 2021 |
The cardiovascular safety profile of escitalopram.
Topics: Adult; Aging; Blood Pressure; Cardiovascular Diseases; Citalopram; Electrocardiography; Female; Hear | 2013 |
The beneficial effect of escitalopram on obsessive-compulsive-related musical hallucinations in elderly patients with hearing impairment: a case series.
Topics: Aged; Aged, 80 and over; Aging; Citalopram; Female; Hallucinations; Hearing Loss; Humans; Male; Musi | 2014 |
Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antidepressive Agents, Second-Generation; Citalopram; Cyclohe | 2014 |
A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation.
Topics: Aged; Aged, 80 and over; Aging; Algorithms; Alzheimer Disease; Antidepressive Agents; Citalopram; Do | 2016 |
Ontogeny of SERT Expression and Antidepressant-like Response to Escitalopram in Wild-Type and SERT Mutant Mice.
Topics: Aging; Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Female; Gene Expression Regulat | 2016 |
Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET.
Topics: Adult; Aging; Brain; Brain Mapping; Citalopram; Corpus Striatum; Female; Hippocampus; Humans; Male; | 2010 |
Aging impairs the antidepressant-like response to citalopram in male rats.
Topics: Aging; Animals; Antidepressive Agents; Citalopram; Depression; Disease Models, Animal; Drinking; Foo | 2010 |
Estradiol valerate elicits antidepressant-like effects in middle-aged female rats under chronic mild stress.
Topics: Aging; Animals; Antidepressive Agents; Chronic Disease; Citalopram; Conditioning, Operant; Depressio | 2010 |
The role of the serotoninergic system in the regulation of thyroid function in old rats.
Topics: Aging; Animals; Citalopram; Male; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serot | 2009 |
Plaque deposition dependent decrease in 5-HT2A serotonin receptor in AbetaPPswe/PS1dE9 amyloid overexpressing mice.
Topics: Aging; Amphetamines; Amyloid beta-Protein Precursor; Aniline Compounds; Animals; Autoradiography; Ci | 2010 |
Citalopram may reduce sympathoadrenal hyperactivity in elderly depressed patients: an open multicenter study in Belgium and Luxembourg.
Topics: Aged; Aging; Analysis of Variance; Antidepressive Agents, Second-Generation; Belgium; Blood Pressure | 2011 |
Longitudinal studies of cerebral glucose metabolism in late-life depression and normal aging.
Topics: Age of Onset; Aged; Aged, 80 and over; Aging; Cerebellum; Citalopram; Cognition Disorders; Depressiv | 2013 |
Information processing bias and pharmacotherapy outcome in older adults with generalized anxiety disorder.
Topics: Adult; Aged; Aging; Anxiety; Anxiety Disorders; Attention; Citalopram; Decision Making; Emotions; Fe | 2013 |
Serotonin modulation of cerebral glucose metabolism in normal aging.
Topics: Adult; Aged; Aging; Brain Mapping; Cerebral Cortex; Citalopram; Female; Functional Laterality; Gluco | 2004 |
Early life trauma decreases glucocorticoid receptors in rat dentate gyrus upon adult re-stress: reversal by escitalopram.
Topics: Aging; Animals; Citalopram; Dentate Gyrus; Disease Models, Animal; Down-Regulation; Glucocorticoids; | 2006 |
Event-related potentials in an emotional go/no-go task and remission of geriatric depression.
Topics: Aged; Aging; Antidepressive Agents; Brain Mapping; Citalopram; Decision Making; Depressive Disorder, | 2007 |
The differential regulation of BDNF and TrkB levels in juvenile rats after four days of escitalopram and desipramine treatment.
Topics: Aging; Animals; Antidepressive Agents, Tricyclic; Brain-Derived Neurotrophic Factor; Chromatography, | 2008 |
The effects of the specific uptake inhibitor Lu 10-171 (citalopram) upon brain indoleamine stores in the maturing mouse.
Topics: 5-Hydroxytryptophan; Aging; Animals; Brain; Citalopram; Hydrazines; Hydroxyindoleacetic Acid; Mice; | 1982 |
Kinetics of citalopram in man; plasma levels in patients.
Topics: Adult; Aged; Aging; Citalopram; Dealkylation; Female; Humans; Kinetics; Male; Middle Aged; Propylami | 1982 |
Comparison of the subregional distributions of the monoamine vesicular transporter and dopamine uptake complex in the rat striatum and changes during aging.
Topics: Aging; Animals; Autoradiography; Citalopram; Dopamine; Dopamine Plasma Membrane Transport Proteins; | 1994 |
The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method.
Topics: Adult; Age Factors; Aging; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; C | 1996 |
Thalamocortical afferents in rat transiently express high-affinity serotonin uptake sites.
Topics: 5,7-Dihydroxytryptamine; Acetylcholinesterase; Afferent Pathways; Aging; Animals; Autoradiography; C | 1996 |
Normal and drug-induced locomotor behavior in aging: comparison to evoked DA release and tissue content in fischer 344 rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Aging; Animals; Brain Chemistry; Chrom | 1998 |
Age-related changes in the capacity, rate, and modulation of dopamine uptake within the striatum and nucleus accumbens of Fischer 344 rats: an in vivo electrochemical study.
Topics: Adrenergic Uptake Inhibitors; Aging; Animals; Citalopram; Corpus Striatum; Desipramine; Dopamine; Do | 1999 |
Effect of serotonin reuptake inhibitor on syndrome development in obese hyperglycemic mice (Umeå ob/ob).
Topics: Aging; Animals; Blood Glucose; Citalopram; Eating; Energy Metabolism; Feces; Female; Hyperglycemia; | 2001 |
Age-dependent changes in serotonergic modulation of yawning in the rat.
Topics: Aging; Animals; Citalopram; Male; Methiothepin; Physostigmine; Rats; Rats, Sprague-Dawley; Ritanseri | 1992 |
Chronic citalopram action and the maturing mouse brain's indoleamine levels.
Topics: Aging; Animals; Animals, Newborn; Brain; Brain Stem; Citalopram; Hydroxyindoleacetic Acid; Mice; Ser | 1990 |
The effects of acute and extended monoamine oxidase inhibition upon 5-hydroxyindoles in maturing mouse brain.
Topics: Aging; Animals; Animals, Newborn; Brain; Brain Chemistry; Brain Stem; Citalopram; Hydroxyindoleaceti | 1991 |
Indoleamine stores in maturing mouse brain reexposed to citalopram following extended uptake inhibition.
Topics: Aging; Animals; Animals, Newborn; Brain Chemistry; Brain Stem; Citalopram; Hydroxyindoleacetic Acid; | 1988 |
Ontogeny of the serotonergic projection to rat neocortex: transient expression of a dense innervation to primary sensory areas.
Topics: Aging; Animals; Autoradiography; Cerebral Cortex; Citalopram; Male; Propylamines; Rats; Rats, Inbred | 1987 |